Stock Market Cafe
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Stock Market Cafe
No Result
View All Result
Home Trading News

Moderna shares fall after company cuts 2021 forecast for Covid vaccine sales

by
November 4, 2021
in Trading News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Moderna shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.

The company said some doses for delivery this year have been shifted to early 2022 amid production issues and as it prioritizes deliveries to low-income countries through COVAX, the U.N.-backed effort to share coronavirus vaccines. It now expects Covid vaccine sales of between $15 billion and $18 billion this year, down from an earlier projection of $20 billion.

RELATED POSTS

These major economies are headed into recession in the next 12 months, Nomura says

More parts of China battle Covid and threats of lockdown as cases spike again

In releasing its third-quarter earnings, Moderna said it is now expecting to deliver between 700 million and 800 million doses this year, down from its previous expectations of between 800 million and 1 billion doses. The company also said it projects sales of $17 billion to $22 billion in 2022.

By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022.

Here’s how Moderna did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

EPS: $7.70 per share versus $9.05 per share expectedRevenue: $4.97 billion versus $6.21 billion expected

“We are humbled to have helped hundreds of millions of people around the world with our COVID-19 vaccine and yet we know our work is not done,” Moderna CEO Stephane Bancel said in a statement.

He said the company is working to ensure the vaccine is available in low-income countries by providing approximately 10% of its 2021 volume to them, and “significantly more” volume next year.

On a post-earnings call with investors, Bancel said the company’s supply chain became “more complex,” impacting international deliveries of its vaccine.

“We’ve increased deliveries to many countries around the world,” he said. “At the beginning of the year, we supplied to just a few large countries.”

Moderna Chief Financial Officer David Meline said the company continues to scale up its production network and is “working to achieve an increase quarter-over-quarter improvement starting in Q4.”

Moderna’s Covid vaccine is the company’s only commercialized product. The earnings report comes two weeks after the Food and Drug Administration authorized booster shots of Moderna’s vaccine to tens of millions of Americans.

The company said Thursday it anticipates commercial booster market sales could be up to $2 billion in 2022.

ShareTweetPin

Related Posts

These major economies are headed into recession in the next 12 months, Nomura says

by
July 5, 2022
0

Thomas Calomiris, a third generation produce vendor, weighs an onion at Eastern Market as the US struggles with rising inflation...

More parts of China battle Covid and threats of lockdown as cases spike again

by
July 5, 2022
0

Covid-related restrictions tightened in parts of China as local cases climbed, while lighter measures such as virus testing linger on...

Natural Gas Soars 700%, Becoming Driving Force in the New Cold War

by
July 5, 2022
0

Quartz India’s reluctance to raise fuel prices has created a major domestic shortage The Indian government has cut excise duty...

The second-half is ‘not looking good’: Strategists on how to weather the market storm

by
July 5, 2022
0

A trader works on the floor of the New York Stock Exchange (NYSE), June 27, 2022. Brendan McDermid | Reuters...

Tesla Pauses Plants After Ending Shaky Quarter With a Production Milestone

by
July 5, 2022
0

Bloomberg US Recession Isn’t Goldman’s Base Case, Macro Strategist Says (Bloomberg) -- The base-case expectation isn’t for a recession in...

Next Post

Hotels: Occupancy Rate Down 6% Compared to Same Week in 2019

Bezos' Blue Origin loses lawsuit against NASA over SpaceX lunar lander contract

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Crocs sees fourth-quarter sales up 42%, CEO Andrew Rees says 2021 was ‘exceptional year’

    0 shares
    Share 0 Tweet 0
  • Buying a car from the factory sounds expensive, but it can actually save you money. Here’s how to do it.

    0 shares
    Share 0 Tweet 0
  • Roth TSP vs. Roth IRA: How Do They Compare?

    0 shares
    Share 0 Tweet 0
  • The states that won’t tax military retirement in 2022

    0 shares
    Share 0 Tweet 0
  • Allbirds stock has plunged 50% in two months, now one top analyst says buy it

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.stockmarket-cafe.com
No Result
View All Result
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.stockmarket-cafe.com